Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...
6d
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...
Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for C
SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the ...
Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...
Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the ...
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...
Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.
RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...
aDepartment of Molecular Medicine, Unit of Cancer Research, University of Southern Denmark, 5000, Odense, Denmark bDepartment of Physics, Chemistry and Pharmacy, University of Southern Denmark, 5000, ...
When new protein structures are reported, it’s often claimed they could lead to the design of therapeutic agents that interact with the proteins more effectively. A new study on short interfering RNAs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback